COGT — Cogent Biosciences Income Statement
0.000.00%
Last trade - 00:00- $668.34m
- $381.26m
Annual income statement for Cogent Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.87 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 90.1 | 75.6 | 148 | 208 | 276 |
| Operating Profit | -82.2 | -75.6 | -148 | -208 | -276 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -74.8 | -72.3 | -140 | -192 | -256 |
| Net Income After Taxes | -74.8 | -72.3 | -140 | -192 | -256 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -74.8 | -72.3 | -140 | -192 | -256 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -179 | -72.3 | -101 | -155 | -201 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -16.5 | -1.87 | -1.73 | -1.94 | -1.94 |